NEW YORK, June 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of NET Power, Inc. (NYSE: NPWR).Shareholders who purchased shares of NPWR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/net-power-inc-loss-submission-form/?id=151910&from=4CLASS PERIOD: June 9, 2023 to March 7, 2 ...

NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Strategy Incorporated (NASDAQ: MSTR). Shareholders who purchased shares of MSTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/strategy-incorporated-loss-submission-form/?id=151576&from=4 CLASS PERIOD: April ...

Company Overview - Cable One, Inc. is a broadband communications provider offering high-speed internet, video, and voice services through its brands, including Sparklight, Fidelity, Hargray, and CableAmerica [3] Allegations and Financial Performance - On May 1, 2025, Cable One reported first-quarter earnings that significantly fell short of analyst expectations and announced plans to suspend its anticipated dividend [4] - Analysts from KeyBanc and Raymond James raised concerns about the company's credibility, noting that the results contradicted prior management statements forecasting growth in subscribers and broadband revenue [4] Market Reaction - Following the earnings report, Cable One's stock price dropped by $109.48 per share, or 41.79%, closing at $152.51 per share on May 2, 2025 [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of violations of federal securities laws related to misleading statements and undisclosed costs impacting financial results [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Canopy Growth, with a deadline of June 3, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses from Canopy Growth between May 30, 2024, and February 6, 2025, are encouraged to discuss their legal options with Faruqi & Faruqi [1][3]. Group 2: Financial Performance and Allegations - The complaint alleges that Canopy Growth and its executives made false or misleading statements regarding the company's financial health, particularly concerning the costs associated with the Claybourne product launch and Storz & Bickel vaporizer devices [5]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs related to the Claybourne product launch and increased indirect costs [6]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [6]. Group 3: Market Reaction - Following the announcement of its financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [8].

URGN Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, May 29, 2025 /PRNewswire/ -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Ibotta, Inc. regarding a class action lawsuit related to the company's initial public offering on April 18, 2024 [1][3] - The lawsuit alleges that Ibotta made false statements and failed to disclose the risks associated with its contract with Kroger, specifically that the contract was at-will and could be terminated without warning [4] - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially become lead plaintiffs and receive updates on the case [5] Company and Industry Summary - Ibotta, Inc. is facing legal challenges due to allegations of misleading investors about the nature of its contract with Kroger, which could impact investor confidence and stock performance [4] - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to misleading statements from companies like Ibotta [6]

Core Viewpoint - ADTRAN Holdings, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following the disclosure of issues with its financial statements [1][2]. Financial Disclosure - On May 13, 2025, ADTRAN announced that its audited consolidated financial statements for the years ended December 31, 2024, and December 31, 2023, as well as its unaudited condensed financial statements for interim periods in 2024, should no longer be relied upon and would be restated [2]. - The company identified at least one additional material weakness in its internal control over financial reporting as of December 31, 2024 [2]. - Following this announcement, ADTRAN's stock price decreased by $0.41, or 4.79%, closing at $8.15 per share on May 14, 2025 [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ADTRAN stockholders who may have suffered losses due to the company's financial disclosures [1][3].

Core Viewpoint - Fulgent Genetics, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following a civil investigative demand from the U.S. Department of Justice regarding false claims submitted under the Uninsured Program [1][2]. Group 1: Company Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Fulgent on behalf of its stockholders [1]. - The investigation is focused on whether Fulgent has engaged in unlawful business practices or violated federal securities laws [1]. - Following the disclosure of the civil investigative demand, Fulgent's stock price decreased by $0.41 per share, or 2.61%, closing at $15.28 per share [2]. Group 2: Legal Context - The civil investigative demand was received by Fulgent from the U.S. Department of Justice, indicating serious scrutiny regarding the company's claims under the Uninsured Program [2]. - The law firm Bragar Eagel & Squire, P.C. specializes in representing investors in complex litigation, which includes securities and derivative cases [4].

SAN FRANCISCO, May 22, 2025 (GLOBE NEWSWIRE) -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA’s Oncologic Drugs Advisory Committee (“ODAC”) voted against the risk/benefit profile of UroGen’s UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (“LG-IR-NMIBC”) for which no drugs are currently FDA-approved. Hagens Berman has opened an investigation in ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][2] Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, leading to an artificial deflation of Cerevel's stock price [2] - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at this artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - The January 18, 2024 Proxy statement from Cerevel is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate [3] - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status [3]